Click in to the video below to hear what some of our audience thought of the previous research meeting.


The Research Meeting 31st October 2016

The drug EPI-589 (owned by Edison Pharmaceuticals) is to be trialled in Parkinson's (PD) in a proof of concept study. EPI-589 was designed to treat rare mitochondrial diseases in children and we now know that mitochondrial dysfunction is a hallmark of genetic types of Parkinson’s. This trial, led by Professor Huw Morris of the Leonard Wolfson Experimental Neurology Centre at UCLH in London, will help us understand whether EPI-589 can improve mitochondrial function in neurons and if so, what benefit this has for people with Parkinson’s.

Professor Morris will be joining us at our research update meeting to talk about mitochondrial dysfunction in PD and how certain drugs are being trialled to treat this recognised characteristic of the disease.

Draft Agenda:

From 3pm Registration

3.25pm Introduction to the meeting - Tom Isaacs, President and Co-founder The Cure Parkinson’s Trust

3.30pm Clinical Trials Results Update - Dr Richard Wyse, Helen Matthews

• Overview of trials underway
• Trials reaching conclusion
• Trials in the planning phase, needing funding

4.00 pm Clinical Trials Recruiting in the London Region: Professor Huw Morris and team

• EPI-589
• Ambroxol
• Families Study
• Simvastatin

4.30 pm Tea / Coffee

4.50 pm Round-up from WPC:

• Best breaking news – Dr Jon Stamford
• Best engagement with industry – David Jones
• Best initiatives by PwP for PwP – David Sangster and Emma Lawton

5.20 pm Parkinson’s World: Tom Isaacs, Dr Jon Stamford and Helen Matthews

5.45 pm Meeting closes – Drinks and Canapés

Book your place(s) below now.

Our first research meeting of 2017 will take place in April (exact date to be confirmed). You can view the research presentations by Professor Roger Barker, Dr Mariah Lelos and Dr Richard Wyse on our You Tube channel filmed at our May 2016 research meeting below :